RMD Open
is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases
Impact Factor: 6.2
Citescore: 7.7
All metrics >>
Authors
RMD Open accepts submissions of a wide range of article types, including original research, analysis and practice articles, and commentaries.
The Author Information section provides specific article requirements to help you turn your work into an article suitable for RMD Open.
Information is also provided on editorial policies and open access.
Latest Articles
Spine:
Spatiotemporal changes in imaging features associated with diffuse idiopathic skeletal hyperostosis (DISH)27 April 2024
Connective tissue diseases:
Disease evolution and organ damage accrual in patients with stable UCTD: a long-term monocentric inception cohort26 April 2024
Sjo[x0308]gren syndrome:
Primary Sjögrens syndrome independently promotes premature subclinical atherosclerosis25 April 2024
VACANCY: Social Media Editor
RMD Open has an exciting vacancy for an enthusiastic Social Media Editor to join the editorial team. The journal is looking to continue to grow its online visibility and reach across various platforms and the Social Media Editor will play a key role in engaging with the journal’s core audience, sharing the latest research and updates in the field, and interacting with the wider community to help achieve this.
Candidates should be educated to postgraduate level with knowledge and experience of the journal’s subject area. Some experience of science communication and social media would be preferred, but the main criteria for the successful applicant will be enthusiasm for the subject area, creativity, curiosity, and an interest in using digital technologies to disseminate scientific research. The role would be ideally suited to a junior researcher or practising clinician, and they can be based anywhere in the world
Application deadline: 31st May 2024
Video Abstract
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Conclusions: Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from weeks 16 to 52.
Find out moreMost Read Articles
Autoimmunity:
Association between sinusitis and incident rheumatic diseases: a population-based study22 February 2024
Rheumatoid arthritis:
Hormonal and reproductive factors in relation to the risk of rheumatoid arthritis in women: a prospective cohort study with 223 526 participants9 January 2024